Eli Lilly and Company

Abbott Laboratories Corporation

Jeffrey Michael Schkeryantz

Albert Khilevich

James Allen Knobelsdorf

Thomas Daniel Aicher

Tony P Tang

Guillermo S Cortez

Fredrik Pehr Marmsater

Todd Michael Groendyke

Daniel Ray Mayhugh

Guoxin Zhu

Scott Eugene Conner

Nathan Bryan Mantlo

Jay R Luly

Paul Leslie Ornstein

Alan M Warshawsky

Jon Kevin Reel

David Andrew Coates

Warren Jaye Porter

Yanping Xu

Patrick Gianpietro Spinazze

Sean Patrick Hollinshead

Quanrong Shen

Kevin Matthew Gardinier

Freddie Craig Stevens

Maria-Jesus Blanco-Pillado

Patric James Hahn

Deyi Zhang

Xiaodong Wang

Matthew John Valli

Bin Liu

Michael J Coghlan

Douglas Linn Gernert

Dana Rae Benesh

Kevin Robert Fales

Nicholas Andrew Magnus

Alan X Wang

John Rowley Wetterau, Ii

Quanrong ' Shen

Todd Micheal Groendyke

Jeffrey Allen Peterson

Jeffrey Michael Witkin

Fredrik Pehr Marmsäter

Dariusz Stanislaw Wodka

Jeffrey Alan Peterson

Yangping Xu

John Rowley Wetterau Ii

Tony Pisal Tang

The invention provides compounds of the formula: (A), pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds, salts, or compositions to treat hyperphosphatemia, chronic kidney disease, and/or the cardiovascular disease associated with chronic kidney disease. 

Condensed thiophene derivatives useful as NaPi-IIb inhibitors

A TARP &#x3b3;8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N;A is andRis as defined herein;its pharmaceutically acceptable salts, uses, and methods for its preparation are described.

[object Object]

The present invention provides compounds of formula (I); pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof. 

Potentiators of glutamate receptors

This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.

This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine.  This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.

The present invention provides certain imidazole carboxamide derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same.

Imidazole carboxamides

The present invention provides a compound of formula (I): pharmaceutical compositions thereof, and methods of using the same, processes for preparing the same, and intermediates thereof. 

The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

Fused heterocyclic derivatives as PPAR modulators

The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I. (Formula I); wherein: (a) R5 is selected from the group consisting of (C&#x2013;C)alkyl, (C&#x2013;C)alkenyl, aryl (C&#x2013;C)alkyl, aryloxy(C&#x2013;C)alkyl, arylthio(C&#x2013;C)alkyl, and further wherein when R5 is alkyl, R5 can optionally combine with W to form a 6 membered cycloheteroalkyl ring that is fused with the oxazole or thiazole ring to which the R5 group is attached; (b) R9 is selected from the group consisting of C&#x2013;Calkyl, C&#x2013;Calkenyl, and arylC&#x2013;Calkyl. (c) Tis selected from the group consisting of C and N, (d) W is selected from the group consisting of CH, C(O)N(R21), N(R21), N(R21)CH, O, OCH, S, and SO; and (e) X is selected from the group consisting of C, CHC, and CCH 

Peroxisome proliferator activated receptor modulators

Compounds having Formula I ##STR1## are useful for modulating the glucocorticoid receptor in a mammal. Also disclosed are pharmaceutical compositions comprising compounds of Formula I and methods of treating immune, autoimmune, inflammatory, adrenal imbalance, cognitive and behavioral diseases in a mammal.

Glucocortiocoid-selective agents

Growing community of inventors

Fishers, IN, United States of America

Jeffrey Michael Schkeryantz